FDA on board with design of mid-stage study of Bellerophon's INOpulse in pulmonary hypertension, trial to start in 2018; shares ahead 11% premarket [Seeking Alpha]
Bellerophon Therapeutics, Inc. (BLPH)
Last bellerophon therapeutics, inc. earnings: 4/6 10:23 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.bellerophon.com
Company Research
Source: Seeking Alpha
Thinly traded nano cap Bellerophon Therapeutics (NASDAQ: BLPH ) is up premarket on modest volume on the heels of its announcement that it has reached agreement with the FDA on the design of a Phase 2 clinical trial evaluating INOpulse in patients with pulmonary hypertension associated with Interstitial Lung Disease (ILD). The study, called iNO-PF, will enroll ~40 patients with pulmonary fibrosis, with half at intermediate-to-high risk of pulmonary hypertension. The FDA has agreed to eliminate the need for right heart catheterization, an invasive procedure that would increase the risk for study participants. The trial should commence in 2018. INOpulse is a drug-device combination system that delivers pulsed doses of nitric oxide. It is portable, suitable for at-home use and automatically adjusts to the patient's breathing patterns to deliver consistent dosing. Now read: Agile prices equity offering; shares down 20% premarket »
Show less
Read more
Impact Snapshot
Event Time:
BLPH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BLPH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BLPH alerts
High impacting Bellerophon Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
BLPH
News
- Bellerophon Therapeutics, Inc. (NASDAQ: BLPH) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Bellerophon Therapeutics, Inc. (NASDAQ: BLPH) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Bellerophon Therapeutics, Inc. (NASDAQ: BLPH) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Bellerophon Therapeutics, Inc. (NASDAQ: BLPH) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Bellerophon Therapeutics, Inc. (NASDAQ: BLPH) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat